All questionsSpecific populations: Nucala (mepolizumab), all indications4 questions · 1 sourceSpecific populationsIs Nucala cleared by the kidneys (renal impairment)?“Patients with Renal Impairment: No clinical trials have been conducted to investigate the effect of renal impairment on the pharmacokinetics of mepolizumab. Based on population pharmacokinetic analyses, mepolizumab clearance was comparable between subjects with creatinine clearance values between 50 and 80 mL/min and patients with normal renal function. There are limited data available in subjects with creatinine clearance values <50 mL/min;” (opens the source at this quote in a new tab)CopyFlag“however, mepolizumab is not cleared renally.” (opens the source at this quote in a new tab)CopyFlagNote: The two passages are one sentence divided by a page break in the Prescribing Information.Does liver impairment affect Nucala?“Patients with Hepatic Impairment: No clinical trials have been conducted to investigate the effect of hepatic impairment on the pharmacokinetics of mepolizumab. Since mepolizumab is degraded by widely distributed proteolytic enzymes, not restricted to hepatic tissue, changes in hepatic function are unlikely to have any effect on the elimination of mepolizumab.” (opens the source at this quote in a new tab)CopyFlagIs Nucala safe for older adults?“Of the total number of patients treated with NUCALA (n = 4106) for severe asthma, HES, EGPA, CRSwNP, and COPD, 1073 (26%) were 65 years of age and older and 241 (6%) were 75 years of age and older [see Clinical Studies (14)]. No overall differences in safety and effectiveness were observed between these patients and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity in some older individuals cannot be ruled out.” (opens the source at this quote in a new tab)CopyFlag“Age: Population pharmacokinetics analyses indicated there was no significant effect of age on mepolizumab clearance.” (opens the source at this quote in a new tab)CopyFlagNote: The first passage pools patients from every approved indication.Pregnancy and breastfeedingCan you breastfeed while taking Nucala?“There is no information regarding the presence of mepolizumab in human milk, the effects on the breastfed infant, or the effects on milk production. However, mepolizumab is a humanized monoclonal antibody (IgG1 kappa), and immunoglobulin G (IgG) is present in human milk in small amounts. Mepolizumab was present in the milk of cynomolgus monkeys postpartum following dosing during pregnancy [see Use in Specific Populations (8.1)]. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NUCALA and any potential adverse effects on the breastfed infant from mepolizumab or from the underlying maternal condition.” (opens the source at this quote in a new tab)CopyFlag